Fundz

Arcus Biosciences

Hayward, California, United States · Biopharma, Biotechnology, Health Care

Arcus Biosciences, Inc. is a clinical-stage, global biopharmaceutical company, focused on developing differentiated molecules and combination therapies for people with cancer.

Key facts

Headquarters
Hayward, California, United States
Employees
618
Industries
Biopharma, Biotechnology, Health Care
Status
Public (RCUS)
Website
arcusbio.com
LinkedIn
Company page

Recent activity at Arcus Biosciences

  • : SEC 8-K (8.01): On October 20, 2026, Arcus Biosciences, Inc. presented new data from its ARC-20 platform study on casdatifan's efficacy in treating clear cell renal cell carcinoma (ccRCC). Key results included an 86% progression-free survival at six months for the first-line treatment with casdatifan plus zimberelimab. The study also evaluated combinations with ipilimumab and cabozantinib, showing promising outcomes without unexpected safety concerns. The findings were relevant as they indicated significant potential for casdatifan as a first-, second-, and late-line treatment for ccRCC, underscoring the drug's strategic importance in their pipeline. Importantly, the event took place on October 20, 2026, making it recent and relevant for investors.
  • : SEC 8-K (8.01): On April 20, 2026, Arcus Biosciences, Inc. announced the discontinuation of the Phase 3 STAR-121 study in collaboration with Gilead Sciences, Inc., due to futility as advised by the Independent Data Monitoring Committee. This trial evaluated the combination of domvanalimab and zimberelimab with chemotherapy against pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer, indicating a strategic setback. Alongside this, Gilead's option rights under the collaboration agreement with Arcus will expire on July 14, 2026, as Gilead has opted not to continue payments for further options within the company's early-stage pipeline. This decision preserves Arcus's rights to key investigational programs and underscores the implications for future collaborations and ongoing patient management strategies.
  • : SEC 8-K (5.02):
  • : SEC 8-K (1.01): On December 18, 2025, Arcus Biosciences, Inc. entered into a First Amendment to the Loan and Security Agreement with various banks and Hercules Capital, Inc. as administrative agent. This amendment modifies the terms of a $150 million term loan facility, providing the Company with $25 million available at its discretion through March 15, 2026, and another $25 million through September 15, 2026. Up to $50 million will be available following the announcement of specific clinical study data, and an additional $50 million will be accessible upon FDA approval of a related drug application. The maturity date of the loan is extended to September 1, 2030, and new performance covenants are introduced based on the loan amount exceeding $200 million, requiring specific financial metrics to be met. This strategic amendment enhances the Company's funding flexibility as it progresses with its drug development initiatives.
  • : SEC 8-K (8.01): On December 12, 2025, Arcus Biosciences, Inc. announced the discontinuation of the Phase 3 STAR-221 study due to futility, as the anti-TIGIT antibody domvanalimab plus anti-PD-1 antibody zimberelimab showed no improvement in overall survival compared to nivolumab plus chemotherapy in an interim analysis. The decision followed a recommendation from the Independent Data Monitoring Committee after reviewing the trial data. Additionally, the STAR-221 and Phase 2 EDGE-Gastric studies will be halted as the company, in collaboration with Gilead Sciences, determines next steps for patients. The company will reallocate its R&D resources to focus on casdatifan and other inflammation and autoimmune programs. Financially, the company anticipates it can support operations until at least the second half of 2028 based on its existing cash and securities.
  • : SEC 8-K (8.01): On December 12, 2025, Arcus Biosciences, Inc. announced the discontinuation of the Phase 3 STAR-221 study. This trial evaluated the effectiveness of the anti-TIGIT antibody domvanalimab combined with the anti-PD-1 antibody zimberelimab and chemotherapy against nivolumab plus chemotherapy for treating advanced gastric and esophageal cancers. The termination was recommended by the Independent Data Monitoring Committee after a pre-specified interim analysis showed no improvement in overall survival for the domvanalimab group compared to the nivolumab treatment. This decision reflects a strategic shift in the company’s clinical focus and potential resource reallocation.
  • : SEC 8-K (8.01): On November 3, 2025, Arcus Biosciences, Inc. completed the sale and issuance of 15,755,000 shares of its common stock, which included 13,700,000 shares from a public offering at $18.25 per share and an additional 2,055,000 shares from the underwriters' option. The underwriters, Leerink Partners LLC and Goldman Sachs & Co. LLC, purchased the shares at $17.155 per share, netting the Company approximately $269.7 million after expenses. The offering was executed under an underwriting agreement dated October 30, 2025, which includes customary representations and covenants. This event reflects a significant capital raise for the Company, enhancing its financial position.
  • : SEC 8-K (8.01): On October 12, 2025, Arcus Biosciences, Inc. announced significant interim results from Arm A1 of the Phase 2 EDGE-Gastric study, focusing on patients with advanced gastric cancer. Interestingly, the study evaluated the safety and efficacy of the combination therapy involving domvanalimab, zimberelimab, and chemotherapy in a group of 41 patients with a median follow-up of 26.4 months. Key findings include a median overall survival (OS) rate of 26.7 months for PD-L1 positive patients and a confirmed overall response rate of 59%. The safety profile appeared favorable with no unexpected safety signals noted. These results may enhance Arcus's strategic positioning in the oncology market as they indicate promising treatment outcomes in this challenging patient population.
  • : Arcus Biosciences, Inc. presents promising data for casdatifan, a HIF-2a inhibitor, aimed at treating metastatic kidney cancer.
  • : Arcus Biosciences Appoints Richard Markus, M.D., Ph.D., as Chief Medical Officer

Leadership

  • Richard Markus, Chief Medical Officer

Verified email and direct lines for Arcus Biosciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Arcus Biosciences files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Arcus Biosciences in the news

Companies similar to Arcus Biosciences

About Arcus Biosciences: questions and answers

What does Arcus Biosciences do?

Arcus Biosciences, Inc. is a clinical-stage, global biopharmaceutical company, focused on developing differentiated molecules and combination therapies for people with cancer.

Where is Arcus Biosciences headquartered?

Arcus Biosciences is headquartered in Hayward, California, United States.

How many employees does Arcus Biosciences have?

Arcus Biosciences has about 618 employees.

What is the latest news on Arcus Biosciences?

On Oct 20, 2026, SEC 8-K (8.01): On October 20, 2026, Arcus Biosciences, Inc. presented new data from its ARC-20 platform study on casdatifan's efficacy in treating clear cell renal cell carcinoma (ccRCC). Key results included an 86% progression-free survival at six months for the first-line treatment with casdatifa

Is Arcus Biosciences a public company?

Yes. Arcus Biosciences is publicly traded under the ticker RCUS.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Arcus Biosciences across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.